Changzhen Shang

10PUBLICATIONS
32CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 17, 2026
AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis.

|Mar 23, 2026
Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus.

Bin Guo, Shaliheng Yerken, Chu Luo

|May 12, 2025
Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma.

Hongkai Zhuang, Chenwei Tang, Wentao Wang

|Jul 19, 2024
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.

Yonglin Hua, Zhixian Sun, Yuxin Xiao

|Apr 30, 2024
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial.

Yajin Chen, Chengyou Du, Shunli Shen

|Mar 05, 2024
CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA.

Chenwei Tang, Hongkai Zhuang, Wentao Wang

Pageof 2

Frequent Collaborators

3 joint publications

Chenwei Tang

2 joint publications

Qingbin Wang

2 joint publications

Yajin Chen

2 joint publications

Zhiqin Xie